fundamental msb (no chart talk), page-14

Wow, as usual you try to extract a colossal amount from a single term.

The International Biotech Licensing Deal of the Year 2010 netted MSB significant amount of money from Cephalon. That deal with Teva is ongoing.

As you have made misleading posts in the past I'm not up with the latest on revenue BUT you can't say the cause of the SP underperformance has nothing to do with Macbank with the negative reports it has issued. It won't fly.

The first one was blatantly misleading, over claimed lack of efficacy of the clinical trials, whereas the testing was for SAFETY. (Petepan is bang up with the differences, in case you're confused.... I know that MSB is the first biotech you've been interested in with HC, usually you invest in blue chips like WOW etc. etc.)

No, and the fact that the SP fell after that ann, and stayed down because it coincided with a sudden obsession in the post GFC sentiment for stocks with revenue streams...you know, the thing you bang on about day after day?

That means the stock fell out of favour, but nothing had gone wrong!

It was just classic leveraging fear and a change in sentiment. I'd be surprised if Macbank hadn't shorted the stock, put it that way. Why do I mention Macbank? because that negative report is what started it, then stop losses were hit, and the fear campaign, started. The stock was doing fine until that point.

Why don't you go home and take a break madamswer? You've put in a colossal effort at trying to discredit me all day, you must be tired.

BTW WOW is coming under pressure in the forseeable future. Investors won't be happy to have paid a premium for a blue chip, only to have it suffer a down turn....with pressure from Aldi etc.So there are risks even with blue chips. Goldmans has issued a warning about CBA, and there is a consensus that it's pretty much reached the limits, the endless stream of dividends is likely to tighten. You never talk about the downside of even premium stocks and there is downside even if you pay through the nose for a stock.

The outlook for an emerging blue chip like MSB is another point entirely. Potential upside is extensive. But you never talk about that do you....